Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.

Warning

This publication doesn't include Faculty of Arts. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

MACHOVÁ POLÁKOVÁ Kateřina POLÍVKOVÁ Václava RULCOVÁ Jana KLAMOVÁ Hana JURČEK Tomáš DVOŘÁKOVÁ Dana ŽÁČKOVÁ Daniela POSPÍŠIL Zdeněk MAYER Jiří MORAVCOVÁ Jana

Year of publication 2010
Type Article in Periodical
Magazine / Source Experimental hematology
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords BCR-ABL; CML; imatinib
Description OBJECTIVE: Of 140 chronic myeloid leukemia patients responding to imatinib with complete cytogenetic remission, 32 exhibited a plateau of BCR-ABL values at >or=0.1% level in a minimum of three subsequent samples (minimal duration, 6 - 9 months). Median follow-up of unchanged BCR-ABL transcript level was 12 months (range, 6 - 64). We tested this group of patient for BCR-ABL mutations to reveal resistance development and to evaluate the risk of disease progression. RESULTS: Mutation was detected by direct sequencing in 9 of 32 patients (28%). Loss of complete cytogenetic remission or 1 log rise of BCR-ABL was observed in five of nine patients at a median of 5 months (range, 4-17) since first detection of mutation. One patient with no mutation relapsed 12 months after the start of the BCR-ABL plateau. In 5 of 32 patients without mutation (16%), BCR-ABL level significantly decreased after the first plateau to levels that stayed unchanged for a median of 11 months (range, 7-28).

You are running an old browser version. We recommend updating your browser to its latest version.